Applications

1479 – 1479r - Substitution of 68Ga-DOTA-peptide PET/CT scanning in lieu of Octreotide for patients undergoing somatostatin receptor diagnostic imaging under MBS item 61369

Find out about the service or technology in this application and the medical condition it addresses. You can also view the application documents, the deadlines for providing consultation input and the outcome of the application when the MSAC process is complete.

  • Status Complete
  • Type New application
  • Pre-PASC consultation -
  • Pre-MSAC consultation -
  • Outcome Supported

Application details

Reason for application

New MBS item.

Service or technology in this application

68Ga-DOTA-peptide positron emission tomography (PET) / computed tomography (CT) scanning has been performed in lieu of 111In-octreotide single-photon emission computed tomography (SPECT)/CT for several years in a number of Australian public hospitals.

Type: Investigative

Medical condition this application addresses

Patients with gastroenteropancreatic neuroendocrine tumours.

Meetings to consider this application

  • PASC meeting: -
  • ESC meeting: -
  • MSAC meeting: 6 - 7 April 2017